Peripheral Arterial Disease Market By Drugs 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Peripheral Arterial Disease Market
Peripheral Arterial Disease Market: By Drugs (Cholesterol, High Blood Pressure and Others Drugs); By Devices (Peripheral Vascular Stents, PTA Guidewires and Others); By Pipeline (Rivaroxaban, DLBS1033 and Others) & By Geography - Forecast (2016-2021)
Report Code : HCR 0263
Updated Date: 03 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Peripheral arterial disease, in which the arteries, other than supplying blood to heart and brain narrow down.  Globally, increasing adoption rates of minimally invasive surgeries and higher healthcare expenditure, rise in the awareness and improving government initiative and growing population of peripheral arterial disease patient are the prime growth drivers of peripheral arterial disease market. In addition, increase in adoption of treatment of peripheral arterial disease, and emerging economies such as China, India and others will create new opportunities for peripheral arterial disease market. However, higher cost of the research and development and increasing risk of side effects of treatment drugs are the key restraints for peripheral arterial disease market.

This report identifies the global peripheral arterial disease market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to peripheral arterial disease market.
 
Peripheral Arterial Disease Market

Geographically, North America dominated the peripheral arterial disease market, because of higher healthcare expenditure and patient awareness. Asia Pacific is projected to have the fastest growth, owing to rapidly increasing aging population, modernizing healthcare structure, and growing medical tourism in developing nations such as China and India in this region. Among all the devices, peripheral vascular stents has the highest market share in peripheral arterial disease market.

This report segments peripheral arterial disease market on the basis of drugs, devices, pipeline and regional market as follows:
  • Peripheral Arterial Disease Market, By Drugs: Cholesterol-Lowering Drugs, High Blood Pressure Lowering Drug, Blood Sugar Regulating Drug, and Blood Clot Preventing Drug
  • Peripheral Arterial Disease Market, By Devices: Peripheral Vascular Stents, Peripheral Transluminal Angioplasty Balloon Catheters, PTA Guidewires, Atherectomy Devices, Chronic Total Occlusion Devices, Aortic Stents, Synthetic Surgical Grafts, Embolic Protection Devices, and Inferior Vena Cava Filters
  • The report has focused study on peripheral arterial disease market by basis of pipeline such as: Rivaroxaban, DLBS1033, Clopidogrel, Propionyl-L-Caritine, and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the peripheral arterial disease market. Some of the major companies’ profiles in detail are as follows:
  • Edward Lifesciences Corporation
  • Boston Scientific Corporation
  • Medtronic Inc.
  • Abbott Laboratories
  • Angioscore Inc.
1. Peripheral Arterial Disease Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Peripheral Arterial Disease Market– Market Forces
   4.1. Drivers
      4.1.1. Increasing adoption rates of minimally invasive surgeries, and higher healthcare expenditure
      4.1.2. Rise in the awareness and improving government initiative
      4.1.3. Growing population of peripheral arterial disease patient
   4.2. Restraints
      4.2.1. Higher cost of research and development
      4.2.2. Increasing risk of side effects of treatment drugs
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of treatment of peripheral arterial disease
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Peripheral Arterial Disease Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Peripheral Arterial Disease Market, By Drugs
   6.1. Cholesterol-Lowering Drugs
   6.2. High Blood Pressure Lowering Drug
   6.3. Blood Sugar Regulating Drug
   6.4. Blood Clot Preventing Drug
7. Peripheral Arterial Disease Market, By Devices
   7.1. Peripheral Vascular Stents
   7.2. Peripheral Transluminal Angioplasty Balloon Catheters
   7.3. PTA Guidewires
   7.4. Atherectomy Devices
   7.5. Chronic Total Occlusion Devices
   7.6. Aortic Stents
   7.7. Synthetic Surgical Grafts
   7.8. Embolic Protection Devices
   7.9. Inferior Vena Cava Filters
8. Peripheral Arterial Disease Market, By Pipeline
   8.1. Rivaroxaban
   8.2. DLBS1033
   8.3. Clopidogrel
   8.4. Propionyl-L-Caritine
   8.5. Others
9. Peripheral Arterial Disease Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Peripheral Arterial Disease – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   11.1. Edward Lifesciences Corporation
   11.2. Boston Scientific Corporation
   11.3. Medtronic Inc.
   11.4. Abbott Laboratories
   11.5. Angioscore Inc.
   11.6. Bayer AG
   11.7. Volcano Corporation
   11.8. Sanofi S.A.
   11.9. Stryker Corporation
   11.10. Johnson & Johnson
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll